Pancreatic cancer

Most pancreatic cancers are pancreatic ductal adenocarcinomas, arising from cells associated with the pancreatic ducts. Neuroendocrine tumors, acinar cancers and other uncommon lesions have different biology. A report saying 'pancreatic mass' is not yet a complete tissue diagnosis.

Upper abdominal or back pain, weight loss, appetite changes and jaundice may lead to investigation. New or abruptly worsening diabetes can be another clue but is not diagnostic. Smoking, chronic pancreatitis and certain inherited variants increase risk. Jaundice with fever or shaking chills, persistent vomiting or severe uncontrolled pain needs prompt assessment.

Pancreas-protocol contrast CT assesses the tumor, nearby vessels and distant spread. MRI or endoscopic ultrasound can clarify selected findings; ultrasound-guided needle sampling commonly provides tissue before systemic treatment. If imaging strongly suggests a removable cancer, the surgical team decides whether a preoperative biopsy is necessary. An inconclusive sample may require expert review or repeat sampling.

CA 19-9 can help establish a baseline and follow response, but bile-duct obstruction can raise it and some people produce little or none. It cannot replace imaging or biopsy. Interpret the trend alongside bilirubin, biliary drainage and the clinical picture.

These categories complement TNM staging. A high-volume pancreatic multidisciplinary team should review the original scans when resectability is uncertain. A smaller scan measurement after treatment does not by itself prove that surgery will be safe or complete.

Discuss germline testing even without a striking family history. It looks for inherited changes that may affect treatment and relatives' risk. Tumor profiling asks a different question: which changes in the cancer could guide a drug or clinical trial? BRCA1/2 and PALB2 findings may support discussion of DNA-repair-directed strategies, but not every alteration has the same evidence.

A minority of tumors have MSI-H/dMMR or another alteration that can open a specific treatment pathway. KRAS mutations are common, but the exact variant matters and a positive result is not an automatic prescription. Ask whether the result changes an established option or only identifies a study.

For suitable resectable disease, surgery is part of a broader plan that usually includes chemotherapy. A pancreatic-head tumor may require pancreaticoduodenectomy, often called a Whipple procedure; body or tail lesions may require distal pancreatectomy. The team considers margin clearance, lymph nodes, recovery and the ability to complete systemic treatment.

Borderline resectable disease commonly receives systemic treatment first, with radiation considered selectively. Restaging then asks whether there is distant progression and whether an operation can achieve a meaningful result. For locally advanced disease, reassessment after treatment can be valuable, but conversion to surgery should not be promised.

For advanced disease, fitness, bilirubin, nutrition, previous therapy and neuropathy help determine the regimen. Options can include modified FOLFIRINOX, gemcitabine with nab-paclitaxel, or a liposomal-irinotecan combination. More drugs are not necessarily better for a person who cannot tolerate them.

In the United States, liposomal irinotecan with oxaliplatin, fluorouracil and leucovorin is approved first-line for adults with metastatic pancreatic adenocarcinoma. Its separate combination with fluorouracil and leucovorin is approved after progression on gemcitabine-based treatment. Liposomal irinotecan is not simply interchangeable with conventional irinotecan.

US olaparib maintenance is specifically for adults with a deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of first-line platinum chemotherapy, with the required companion test. This is a maintenance setting, not a general treatment for every BRCA-related finding or for disease already progressing on platinum.

Daraxonrasib: who the option is for

Daraxonrasib is a RAS inhibitor approved in the United States for adults with metastatic pancreatic adenocarcinoma after at least one systemic therapy, or when multiagent systemic treatment is unsuitable. Its label does not require a particular KRAS G12 variant. This adds a treatment option within defined circumstances; it does not replace every first-line regimen. Skin and mouth toxicity, diarrhea, lung inflammation and gastrointestinal perforation require a prevention and monitoring plan.

A blocked bile duct may need endoscopic or other drainage, especially when infection is suspected or jaundice prevents treatment. Vomiting from obstruction at the stomach outlet needs its own assessment; simply increasing anti-nausea medicine may not solve the cause.

Loss of pancreatic enzymes can cause greasy stools, bloating and weight loss despite eating. Pancreatic enzyme replacement and dietary support may help when exocrine insufficiency is present. Diabetes management, pain medicines and selected nerve-block procedures can be integrated with cancer treatment. Report a swollen painful leg, sudden breathlessness or chest pain urgently because pancreatic cancer can increase clot risk.

Individualized mRNA neoantigen vaccines have produced durable tumor-directed immune responses in early postoperative studies. The published follow-up involved a small phase I cohort receiving several treatments; an association between an immune response and later recurrence does not by itself prove how much benefit the vaccine caused. These findings justify further trials rather than routine replacement of chemotherapy.

CT041, a CLDN18.2-directed CAR T-cell approach, is also being investigated in pancreatic cancer. Its approval for a defined gastric/GEJ population in China must not be extrapolated to pancreatic cancer. A study needs separate review of its exact population, phase, center and current enrollment; travel should follow confirmation from the treating research team.

Follow-up combines symptoms, weight, function, imaging and relevant markers. After surgery, it also checks recovery, enzyme needs and diabetes. When treatment stops helping, distinguish progression from intolerance and reconsider the goal rather than repeating the same regimen by default.

• Bring original pancreas-protocol scans, pathology and surgical assessments, including the named vessels involved.
• Include bilirubin and CA 19-9 trends, biliary stent details, treatment dates and responses.
• Bring germline/tumor results and a record of weight, food intake, bowel changes, pain and diabetes medicines.

Ask whether a specialist surgical review could change the plan, which test matters before the next treatment and what support will make that treatment achievable.